These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38839457)

  • 1. Lessons learned from the Eµ-TCL1 mouse model of CLL.
    Floerchinger A; Seiffert M
    Semin Hematol; 2024 Jun; 61(3):194-200. PubMed ID: 38839457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal analyses of CLL in mice identify leukemia-related clonal changes including a Myc gain predicting poor outcome in patients.
    Öztürk S; Paul Y; Afzal S; Gil-Farina I; Jauch A; Bruch PM; Kalter V; Hanna B; Arseni L; Roessner PM; Schmidt M; Stilgenbauer S; Dietrich S; Lichter P; Zapatka M; Seiffert M
    Leukemia; 2022 Feb; 36(2):464-475. PubMed ID: 34417556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-181b as a therapeutic agent for chronic lymphocytic leukemia in the Eµ-TCL1 mouse model.
    Bresin A; Callegari E; D'Abundo L; Cattani C; Bassi C; Zagatti B; Narducci MG; Caprini E; Pekarsky Y; Croce CM; Sabbioni S; Russo G; Negrini M
    Oncotarget; 2015 Aug; 6(23):19807-18. PubMed ID: 26090867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD5+CD23+ leukemic cell populations in TCL1 transgenic mice show significantly increased proliferation and Akt phosphorylation.
    Efanov A; Zanesi N; Nazaryan N; Santanam U; Palamarchuk A; Croce CM; Pekarsky Y
    Leukemia; 2010 May; 24(5):970-5. PubMed ID: 20357824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Constitutive activation of Lyn kinase enhances BCR responsiveness, but not the development of CLL in Eµ-TCL1 mice.
    Kohlhas V; Hallek M; Nguyen PH
    Blood Adv; 2020 Dec; 4(24):6106-6116. PubMed ID: 33351104
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ROR1 can interact with TCL1 and enhance leukemogenesis in Eμ-TCL1 transgenic mice.
    Widhopf GF; Cui B; Ghia EM; Chen L; Messer K; Shen Z; Briggs SP; Croce CM; Kipps TJ
    Proc Natl Acad Sci U S A; 2014 Jan; 111(2):793-8. PubMed ID: 24379361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling.
    Greene JT; Mani R; Ramaswamy R; Frissora F; Yano M; Zapolnik K; Harrington B; Wasmuth R; Tran M; Mo X; McKenna M; Rangnekar VM; Byrd JC; Bondada S; Muthusamy N
    Blood Adv; 2019 Apr; 3(8):1255-1266. PubMed ID: 30987970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the splenic microenvironment in chronic lymphocytic leukemia development in Eµ-TCL1 transgenic mice.
    Collard JP; McKenna MK; Noothi SK; Alhakeem SS; Rivas JR; Rangnekar VM; Muthusamy N; Bondada S
    Leuk Lymphoma; 2022 Aug; 63(8):1810-1822. PubMed ID: 35258388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia.
    Yan XJ; Albesiano E; Zanesi N; Yancopoulos S; Sawyer A; Romano E; Petlickovski A; Efremov DG; Croce CM; Chiorazzi N
    Proc Natl Acad Sci U S A; 2006 Aug; 103(31):11713-8. PubMed ID: 16864779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemia.
    Bresin A; D'Abundo L; Narducci MG; Fiorenza MT; Croce CM; Negrini M; Russo G
    Cell Death Dis; 2016 Jan; 7(1):e2071. PubMed ID: 26821067
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
    McClanahan F; Riches JC; Miller S; Day WP; Kotsiou E; Neuberg D; Croce CM; Capasso M; Gribben JG
    Blood; 2015 Jul; 126(2):212-21. PubMed ID: 25979947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
    Zanesi N; Aqeilan R; Drusco A; Kaou M; Sevignani C; Costinean S; Bortesi L; La Rocca G; Koldovsky P; Volinia S; Mancini R; Calin G; Scott CP; Pekarsky Y; Croce CM
    Cancer Res; 2006 Jan; 66(2):915-20. PubMed ID: 16424025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects.
    Eiken AP; Smith AL; Skupa SA; Schmitz E; Rana S; Singh S; Kumar S; Mallareddy JR; de Cubas AA; Krishna A; Kalluchi A; Rowley MJ; D'Angelo CR; Lunning MA; Bociek RG; Vose JM; Natarajan A; El-Gamal D
    Cancer Res Commun; 2024 May; 4(5):1328-1343. PubMed ID: 38687198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD74 is dispensable for development of chronic lymphocytic leukemia in
    Barthel R; Fedorchenko O; Velmans T; Rosen N; Nguyen PH; Reinart N; Florin A; Herling M; Hallek M; Fingerle-Rowson G
    Leuk Lymphoma; 2020 Dec; 61(12):2799-2810. PubMed ID: 32667245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia.
    Walker JS; Hing ZA; Harrington B; Baumhardt J; Ozer HG; Lehman A; Giacopelli B; Beaver L; Williams K; Skinner JN; Cempre CB; Sun Q; Shacham S; Stromberg BR; Summers MK; Abruzzo LV; Rassenti L; Kipps TJ; Parikh S; Kay NE; Rogers KA; Woyach JA; Coppola V; Chook YM; Oakes C; Byrd JC; Lapalombella R
    J Hematol Oncol; 2021 Jan; 14(1):17. PubMed ID: 33451349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.
    Gorgun G; Ramsay AG; Holderried TA; Zahrieh D; Le Dieu R; Liu F; Quackenbush J; Croce CM; Gribben JG
    Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6250-5. PubMed ID: 19332800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell antigen receptor expression and phosphatidylinositol 3-kinase signaling regulate genesis and maintenance of mouse chronic lymphocytic leukemia.
    Schmid VK; Khadour A; Ahmed N; Brandl C; Nitschke L; Rajewsky K; Jumaa H; Hobeika E
    Haematologica; 2022 Aug; 107(8):1796-1814. PubMed ID: 35021605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL.
    Iacovelli S; Hug E; Bennardo S; Duehren-von Minden M; Gobessi S; Rinaldi A; Suljagic M; Bilbao D; Bolasco G; Eckl-Dorna J; Niederberger V; Autore F; Sica S; Laurenti L; Wang H; Cornall RJ; Clarke SH; Croce CM; Bertoni F; Jumaa H; Efremov DG
    Blood; 2015 Mar; 125(10):1578-88. PubMed ID: 25564405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.
    Lewis R; Maurer HC; Singh N; Gonzalez-Menendez I; Wirth M; Schick M; Zhang L; Isaakidis K; Scherger AK; Schulze V; Lu J; Zenz T; Steiger K; Rad R; Quintanilla-Martinez L; Espeli M; Balabanian K; Keller U; Habringer S
    Leukemia; 2021 Oct; 35(10):2895-2905. PubMed ID: 34363012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-Analysis Reveals Significant Sex Differences in Chronic Lymphocytic Leukemia Progression in the
    Koch M; Reinartz S; Saggau J; Knittel G; Rosen N; Fedorchenko O; Thelen L; Barthel R; Reinart N; Seeger-Nukpezah T; Reinhardt HC; Hallek M; Nguyen PH
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32698538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.